Kidney effects in long term exposed lead smelter workers

L Gerhardsson, D R Chettle, V Englyst, G F Nordberg, H Nyhlin, M C Scott, A C Todd, O Vesterberg

Abstract
Occupational exposure to lead may cause kidney damage. This study was carried out on a cohort of 70 active and 30 retired long term exposed lead smelter workers. Their kidney function was compared with 31 active and 10 retired truck assembly workers who had no occupational exposure to lead. The lead workers had been regularly followed up with measurements of lead concentration in blood since 1950. Previous exposure to lead was calculated as a time integrated blood lead index for each worker. Blood and urine samples were obtained from all subjects. The concentration of lead in blood (B-Pb) and urine (U-Pb) was analysed. The urinary concentrations of several sensitive indicators of early tubular (U-β2-microglobulin (U-β2-m); U-N-acetyl-β-glucosaminidase (U-NAG)) and glomerular kidney damage (U-albumin) were determined. The B-Pb and U-Pb values were significantly higher among active and retired lead workers compared with their corresponding control groups. The highest concentrations were found among the active lead workers. The concentrations of the parameters of kidney function investigated were of the same magnitude for exposed workers and controls. No clinical signs of renal impairment were found among the workers. No correlations of clinical importance existed between concentrations of U-albumin, U-β2-m, and U-NAG activity on the one hand and the concentrations of B-Pb, cumulative blood lead index, U-Pb, and lead concentrations in the calcaneus and tibia on the other, among lead workers and controls. Despite many years of moderate to heavy exposure to lead, particularly for the retired lead workers, no signs of adverse effects on the kidney such as early tubular or glomerular malfunction were found. Reversible changes in kidney function during the 1950s and 1960s could not be excluded, however, due to a greater exposure to lead during that time.

Inorganic lead is widely distributed. As well as exposure from the general environment, exposure to lead may occur in lead mines, lead smelting and refining operations, storage battery factories, brass foundries, and glass works. In the working environment exposure may occur both through inhalation and through ingestion of contaminated food, drinks, and snuff.

The Rönnskär smelter in the northern part of Sweden has specialised in the processing of complex and contaminated raw materials. In addition to the main products of copper and lead, the company, Boliden Mineral AB, operates plants for the recovery of precious metals, special products, and sulphur products from the raw materials. The processes have mostly been developed within the company.

In the production of lead, the smelter primarily uses lead concentrates from the company, and also flue dust containing lead obtained as a byproduct from the company’s plant for the production of copper and zinc concentrates. Flash smelting is used for the production of lead. The concentrate is smelted in an electric furnace without previous roasting or sintering, and the furnace lead is then converted and refined. Lead production at the smelter varies between 40 000 and 70 000 tonnes a year. Many employees start work at the smelter between the ages of 20 and 30 and continue their work up to retirement. A duration of employment of 30 to 40 years is therefore not unusual.
Kidney effects in long term exposed lead smelter workers

Absorbed lead is excreted from the body mainly through the urine and the faeces. The excretion into urine is mostly through glomerular filtration as indicated by experimental animal studies. Inorganic lead can affect the human body in several ways. The exposure may disturb haeme synthesis, erythrocyte survival, the nervous system, the gastrointestinal tract, reproduction, and possibly also the cardiovascular system. Lead may also cause kidney damage. Interstitial nephritis, tubular damage, and at a late stage of the disease, glomerular damage, have also been reported. Functionally, these effects on the kidney may cause leakage of enzymes from tubular cells and excretion of low and high molecular weight proteins into the urine.

Hypertension is a well recognised risk factor in the progression of renal failure. Exposure to lead has been associated with hypertension even with only modest increases in blood lead concentrations. Toxicological studies have also documented an association between increased absorption of lead and hypertension. The effects of lead appear to be mediated through toxic effects on the kidneys and by direct action on vascular smooth muscle. Lead can inhibit renal tubular reabsorption of sodium directly, probably by acting on Na⁺/K⁺ ATPase to alter intracellular concentrations of sodium and calcium ions. A change in cellular volume may raise plasma renin activity. Lead may also affect cytosolic free calcium ion concentration in juxtaglomerular cells. Finally, lead may alter renal vascular reactivity to α-adrenergic agents.

In this study sensitive indicators of early tubular or glomerular damage to the kidney have been analysed in long term exposed lead smelter workers. Due to the unique records of blood lead (B-Pb) concentrations collected at the smelter since 1950, it has been possible to relate the findings on kidney function in each worker to his previous exposure to lead.

Material and methods

Seventy active and 30 retired long term exposed lead smelter workers participated in our study. Their kidney function was compared with a group of 31 active and 10 retired truck assembly workers with no occupational exposure to lead. The truck assembly plant is situated in the city of Umeå some 140 kilometers from the smelter.

Blood and urine samples were obtained from all subjects. The urine sampling period was about four hours. After collection, the urine was immediately checked with dipsticks (Ecur-4; test; Boehringer Mannheim, Germany) for signs of albumin, glucose, erythrocytes, and leucocytes, and the pH was determined. The samples were then immediately put into a freezing room. After transportation in a deep frozen state, the urinary concentrations of β₂-microglobulin (U-β₂-m), albumin, and the tubular enzyme N-acetyl-β-glucosaminidase (U-NAG) were analysed at the Department of Medical Chemistry, National Institute of Occupational Health, Solna, Sweden.

Urinary β₂-microglobulin concentration was analysed by radioimmunoassay (RIA; Pharmacia, Uppsala, Sweden). Only urine samples with a pH higher than 5.5 were used for the determinations, as a time and temperature dependent degradation of U-β₂-m occurs when the urinary pH is less than 5.5.

U-Albumin concentration was determined by zone immunoelectrophoresis assay. The standard curve was prepared by diluting Seronorm (Nycomed, Oslo, Norway) in the electrophoresis buffer. Samples of 10 µl were analysed in duplicate. Mostly the results showed a good agreement between each pair of values. The accuracy of the method for U-albumin determination was checked and scored well in interlaboratory comparisons organised in the European Community by a laboratory in Amsterdam, as well as in a study organised by Centers for Disease Control in Atlanta, USA. The quality control programme also included low concentrations in the normal range.

Urinary N-acetyl-β-glucosaminidase activity was measured after gel filtration of the urine samples on Sephadex G50 (Pharmacia) to remove interference. The assay was carried out with a kit and recommendations from Boehringer Mannheim, Germany. The U-NAG analyses showed good agreement with results obtained by The Amsterdam Laboratory.

The values of the urinary parameters were adjusted for dilution by the concentrations of creatinine in urine.

Lead concentrations in venous blood and urine samples were determined in duplicate at the company’s research laboratory by atomic absorption spectrophotometry (AAS) with a Perkin Elmer 5000-Z combined with HGA-500 (standards (B901, B902, U108) from Nycomed, Oslo, Norway). The analyses of blood lead at the smelter started in 1950. Emission spectrometry was used for the analyses during the period 1950–69. This method was replaced by AAS in 1967. The accumulated exposure to lead since 1950 was calculated as a cumulative blood lead index by a summation of the annual mean blood lead concentrations for each worker expressed in µmol/l.

During the 1950s and the 1960s the research laboratory exchanged blood samples for lead determination with laboratories in West Germany and the United Kingdom. Since the 1970s, the laboratory has participated in a national quality control programme organised by the National Board of Occupational Health and Safety in Stockholm, Sweden and the results have always been in good agreement with the expected concentrations.
Many other parameters were also analysed in the blood samples—for example, plasma (P)-creatinine and haemoglobin concentrations, sedimentation rate, and red and white cell counts. These analyses, together with determination of the creatinine concentration in urine (U-creatinine) were performed at the department of clinical chemistry, University Hospital of Umeå and monitored by routine quality control procedures.

The lead concentrations in the calcaneus and tibia of all participants were analysed by x-ray fluorescence. The method has been described in detail elsewhere.23-26

An occupational and medical history regarding working sites at the smelter, alcohol consumption, smoking habits, food intake, and hobbies involving lead was obtained from each worker, and a control was matched by the use of a computerised questionnaire. A physical examination of all subjects was also made.

STATISTICS
As group sizes and variances differed considerably between the groups, non-parametric statistical methods—for example, Kruskal-Wallis one way analysis of variance, Mann-Whitney U test, and Spearman rank order correlation coefficients—were used. p Values less than 0·05 (Mann-Whitney two tailed tests) were considered statistically significant.

Table 1  Mean (SD) values for age, time of employment, and duration of retirement in smelter workers and referents

<table>
<thead>
<tr>
<th></th>
<th>Exposed workers</th>
<th>Referents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active workers</td>
<td>37.4 (12.6)</td>
<td>43.2 (13.0)</td>
</tr>
<tr>
<td>Retired workers</td>
<td>67.9 (4.7)</td>
<td>69.5 (3.2)</td>
</tr>
<tr>
<td>Employment time (y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active workers</td>
<td>14.3 (9.7)</td>
<td>16.4 (8.3)</td>
</tr>
<tr>
<td>Retired workers</td>
<td>32.6 (6.3)</td>
<td>20.9 (9.6)</td>
</tr>
<tr>
<td>Duration of retirement (y)</td>
<td>7.4 (4.8)</td>
<td>5.1 (2.6)</td>
</tr>
</tbody>
</table>

Table 2  Blood lead concentration, cumulative blood lead index, and lead concentrations in calcaneus and tibia in smelter workers and referents

<table>
<thead>
<tr>
<th></th>
<th>Exposed workers</th>
<th>Range</th>
<th>Referents</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-Pb  (µmol/l):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active workers</td>
<td>1-54</td>
<td>0.24 to 2.29</td>
<td>0-20</td>
<td>0.08 to 0.60</td>
</tr>
<tr>
<td>Retired workers</td>
<td>0.48</td>
<td>0.16 to 1.01</td>
<td>0.17</td>
<td>0.11 to 0.59</td>
</tr>
<tr>
<td>Cumulative blood lead index (µmol/l):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active workers</td>
<td>17.85</td>
<td>3.3 to 104.20</td>
<td>12.2</td>
<td>-12.7 to 43.0</td>
</tr>
<tr>
<td>Retired workers</td>
<td>72.20</td>
<td>21.3 to 98.20</td>
<td>30.2</td>
<td>-7.1 to 56.7</td>
</tr>
<tr>
<td>Lead concentrations in calcaneus (µg/g bone mineral):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active workers</td>
<td>48.6</td>
<td>0.4 to 217.8</td>
<td>12.2</td>
<td>-12.7 to 43.0</td>
</tr>
<tr>
<td>Retired workers</td>
<td>100.2</td>
<td>34.8 to 188.9</td>
<td>30.2</td>
<td>-7.1 to 56.7</td>
</tr>
<tr>
<td>Lead concentrations in tibia (µg/g bone mineral):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active workers</td>
<td>13.0</td>
<td>-4.1 to 72.8</td>
<td>3.4</td>
<td>-9.4 to 13.3</td>
</tr>
<tr>
<td>Retired workers</td>
<td>39.3</td>
<td>2.9 to 73.4</td>
<td>12.0</td>
<td>-6.7 to 23.7</td>
</tr>
</tbody>
</table>
positively correlated with both B-Pb and the found and calcaneus concentrations and between index (r = 0.022) and cumulative blood lead concentration, lead has decreased considerably at the smelter over the years. From 1950 to 1987 the mean blood lead concentration among lead workers decreased from 3.0 µmol/l to about 1.6 µmol/l. For workers exposed to lead at other metal producing plants, the corresponding decrease was from 2.7 to 0.8 µmol/l.

It is well known that occupational exposure to lead
may effect renal function.2 3 27 28 The cells lining the proximal tubules appear to be the tissue in the kidney most sensitive to lead.29 At concentrations of lead in blood of around 1-6 μmol/l, lead may partially inhibit the metabolic activation of vitamin D, a transformation that occurs in these cells.30

Two principal stages of effects of lead on the kidneys have been defined. Stage I is the period of acute effects and is limited to functional and morphological changes in proximal tubular cells. It is manifest clinically as a decrease in energy dependent transport functions, including aminoaciduria, glucosuria, and changes in specific ion transport. The functional changes are thought to be related to an effect on mitochondrial respiration and phosphorylation. The intranuclear inclusion bodies are a characteristic feature of stage I nephropathy. These occur in the cells lining the proximal tubules at blood lead concentrations of 2-4 μmol/l and are composed of lead protein complexes.4,12 They are thought to serve as a protective temporary storage mechanism by which soft tissue lead is incorporated into a non diffusible form, thereby reducing the cytoplasmic concentration of lead available to disrupt essential cell function.5

Stage II is defined as a chronic irreversible condition, characterised by interstitial fibrosis, tubular atrophy, and dilatation and arteriosclerotic changes.15 31 52

Older studies of the effects of lead on kidney function have often used parameters such as concentration of blood urea nitrogen (BUN), serum (S)-creatinine, or total urinary protein concentration as measurements of renal function. Due to the great reserve capacity of the kidney, however, these measures of excretory function can be in the normal range despite considerable impairment of renal function. Blood urea nitrogen and S-creatinine concentrations will increase only when about two thirds of kidney function is lost, and are thus unlikely to detect early or moderate loss of renal function due to lead.

The excretion of low molecular weight proteins in the urine may be a sensitive indicator of early renal injury. Both β₂-m and retinol binding protein are freely filtered from the plasma by the renal glomerulus and are taken up by the proximal tubular cells where they are catabolised. The reabsorption of these proteins by the normal kidneys is nearly complete at 99.97% of the filtered load. Thus their concentration in urine is a sensitive index of altered proximal tubular function.33

Another sensitive indicator of renal injury, especially for the detection of possible damage to proximal tubules by lead is multiple enyzme analysis.34 Activity of N-acetyl-β-D-glucosaminidase, a lysosomal enzyme present in the brush borders of the proximal tubular cells, has been shown to be raised in urine at the early stages of renal injury, before abnormalities in excretory function take place.32 Thus both U-β₂-m concentration and U-NAG activity were chosen as sensitive markers of early tubular damage in our study.

The glomerulus is the main barrier to the renal elimination of high molecular weight (> 40 000) proteins. The filtration of proteins by the glomerulus is both size and charge selective. Loss of selectivity of the glomerular filter can be detected early by measurement of the urinary excretion of high molecular weight proteins, predominantly albumin. Other larger proteins such as IgG, IgM, and α₂-macroglobulin may also show increased excretion into the urine. In this study albumin was selected as a sensitive indicator of early glomerular damage.

Chronic occupational exposure to lead resulting in concentrations of blood lead exceeding 1-9 μmol/l has been associated with subsequent renal disease.35 Other authors2 36-39 have suggested a higher limit for kidney effects of around 3 μmol/l. A large proportion of the lead workers in this study have exceeded these limits, especially during the 1950s and 1960s. Thus reversible changes in the tubular function for some workers who were active during these times could not be excluded.

Selenvan et al found an excess mortality from chronic renal disease in a cohort study of 1987 men employed in a lead smelter between 1940 and 1965.40 The risk of death from renal disease increased with increasing duration of employment. In a cohort study of 4519 battery plant workers and 2300 lead production workers, a significant number of excess deaths from chronic nephritis was noted in both cohorts.41 42 The mean blood lead concentration for 1326 of the battery plant workers with three or more analyses was 3-0 μmol/l, and 278 had means of 3-4 μmol/l or more. For 537 lead production workers in four plants the mean was 3-9 μmol/l. An increased mortality from chronic renal diseases has also been reported in two other cohort studies,43 44 among retired lead battery workers and among lead smelter workers who had received the diagnosis of lead poisoning. In each of these four investigations, a two to threefold increase in deaths from chronic nephritis has been noted.

The smelter workers studied have had a continuous and long term exposure to lead. This is shown by a median cumulative blood lead index of 72.2 μmol/l among the retired lead workers, with corresponding median bone lead concentrations in tibia and calcaneus of 39.3 and 100.2 μg/g bone mineral respectively (table 2). Despite an exposure of this magnitude, however, no signs of adverse effects on the kidney such as early tubular or glomerular damage have been found among the workers in the lead smelter. Similar results have been reported by Buchet et al.7 Bernard et al found no change in the
Kidney effects in long term exposed lead smelter workers

urinary excretion of β₂-m, albumin, transferrin, IgG and several enzymes in a study of 25 lead smelter workers with a mean B-Pb concentration of 2.1 μmol/l.\(^4\) Schaller \textit{et al} found no increased renal excretion of proteins in workers occupationally exposed to lead (B-Pb concentration around 2.5-4.5 μmol/l).\(^5\) A decreased glomerulat filtration rate but no increase in urinary excretion of β₂-m or amino acids was found among 28 workers at a lead smelter with a mean B-Pb concentration of 3.0 μmol/l.\(^6\) Meyer \textit{et al} found a pronounced increase in urinary excretion of NAG in a study of 29 workers with various occupations connected with exposure to lead.\(^7\) Similar findings were reported by Verschoor \textit{et al} who found a slight increase in urinary excretion of NAG and retinol binding protein (RBP) with increasing B-Pb concentrations in a study of 155 men working with lead (mean value of B-Pb concentration 2.3 μmol/l).\(^8\) Thus it has been suggested that U-NAG activity would be the only marker to respond at an early stage of lead nephropathy.\(^9\) Nevertheless, increased urinary excretion of NAG was not found among long term exposed lead smelter workers in our study. The lack of signs of kidney damage among the lead workers in this investigation agrees with earlier reported results from an epidemiological study of mortality from exposure to lead at the same smelter.\(^10\) In a cohort of 437 lead smelter workers, two cases of uraemia from kidney diseases that might be caused in part by exposure to lead was in agreement with the expected number of 2.2.

In conclusion, the extent to which low to moderate occupational exposure to lead contributes to lead nephropathy is still debated as published results have been conflicting. Available data from cohorts with long term low exposure to lead are not sufficient to make a proper judgement. Too few studies have been carried out to provide adequate information about the cumulative systemic uptake of lead with time. Because renal changes may be subtle, the number of subjects in the study population must be considered. To be able to predict excessive lead absorption and signs of early kidney damage reliably, suitable biological monitoring techniques have to be further developed and validated.

Financial support was given by the Swedish Work Environment Fund, projects no 87-0932 and 89-0099.

The Birmingham group has received extensive financial support from the UK Health and Safety Executive, and support for ACT from the UK Colt Foundation.

Mrs H Anundi, H Saranius, and B Åkerlund are acknowledged for the protein determinations.

Requests for reprints to: Dr L Gerhardsson, Department of Occupational and Environmental Medicine, Lund University, S-221 85 Lund, Sweden.

Correspondence and editorials

The British Journal of Industrial Medicine welcomes correspondence relating to any of the material appearing in the journal. Results from preliminary or small scale studies may also be published in the correspondence column if this seems appropriate. Letters should be not more than 500 words in length and contain a minimum of references. Table and figures should be kept to an absolute minimum. Letters are accepted on the understanding that they may be subject to editorial revision and shortening.

The journal now also publishes editorials which are normally specially commissioned. The Editor welcomes suggestions regarding suitable topics; those wishing to submit an editorial, however, should do so only after discussion with the Editor.